Literature DB >> 2053787

Evaluation of a pen injector system for growth hormone treatment.

P D Gluckman1, W S Cutfield.   

Abstract

The increasing use of human growth hormone (hGH) treatment has resulted in the introduction of a number of alternative delivery systems to conventional syringe and needle administration. We examined patients' evaluation of a new delivery system, the Kabipen (Kabi-Vitrum). We also assessed the accuracy of hGH delivery by the Kabipen. Of the 77 survey respondents 13 had used only the Kabipen, 14 the syringe only, and 50 had used both systems. Altogether 46 (92%) of those who had used both systems preferred the Kabipen. Children over 10 years were more likely to self administer hGH with the Kabipen (64%) than syringe (25%). Patient instructions, convenience of use, and comfort of use were rated better for the Kabipen than syringe. With a dose setting of 2 units the Kabipen delivered a mean (SD) of 1.997 (0.073) units with 102.5% recovery from a unit cartridge. In summary the Kabipen is an accurate device clearly preferred by the majority of hGH recipients surveyed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2053787      PMCID: PMC1793174          DOI: 10.1136/adc.66.6.686

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

1.  Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen.

Authors:  N Saurbrey; S Arnold-Larsen; B Møller-Jensen; C Kühl
Journal:  Diabet Med       Date:  1988-03       Impact factor: 4.359

2.  Contribution of dose and frequency of administration to the therapeutic effect of growth hormone.

Authors:  P J Smith; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

3.  Dose dependence of growth response to human growth hormone in growth hormone deficiency.

Authors:  M A Preece; J M Tanner; R H Whitehouse; N Cameron
Journal:  J Clin Endocrinol Metab       Date:  1976-03       Impact factor: 5.958

4.  Effects of two years of methionyl growth hormone therapy in two dosage regimens in prepubertal children with short stature, subnormal growth rate, and normal growth hormone response to secretagogues. (Dutch Growth Hormone Working Group).

Authors:  J M Wit; M H Fokker; S M de Muinck Keizer-Schrama; W Oostdijk; M Gons; B J Otten; H A Delemarre-Van de Waal; M Reeser; J J Waelkens
Journal:  J Pediatr       Date:  1989-11       Impact factor: 4.406

5.  Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children.

Authors:  K W Kastrup; J S Christiansen; J K Andersen; H Orskov
Journal:  Acta Endocrinol (Copenh)       Date:  1983-10

6.  Daily subcutaneous administration of human growth hormone in growth hormone deficient children.

Authors:  K Albertsson-Wikland; O Westphal; U Westgren
Journal:  Acta Paediatr Scand       Date:  1986-01

7.  A dose-response curve for human growth hormone.

Authors:  S D Frasier; G Costin; B M Lippe; T Aceto; P F Bunger
Journal:  J Clin Endocrinol Metab       Date:  1981-12       Impact factor: 5.958

8.  Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure.

Authors:  V H Koch; B M Lippe; P A Nelson; M I Boechat; B M Sherman; R N Fine
Journal:  J Pediatr       Date:  1989-09       Impact factor: 4.406

9.  Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome.

Authors:  R G Rosenfeld; R L Hintz; A J Johanson; B Sherman; J A Brasel; S Burstein; S Chernausek; P Compton; J Frane; R W Gotlin
Journal:  J Pediatr       Date:  1988-08       Impact factor: 4.406

10.  Turner's syndrome: treatment of 203 patients with recombinant human growth hormone for one year. A multicentre study.

Authors:  K Takano; K Shizume; I Hibi
Journal:  Acta Endocrinol (Copenh)       Date:  1989-05
  10 in total
  7 in total

1.  Evaluation of a pen injector system for growth hormone treatment.

Authors:  G Hamill; R Stanhope
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

2.  Optimum method for growth hormone treatment.

Authors:  R N Wild
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

3.  Growth hormone treatment without a needle using the Preci-Jet 50 transjector.

Authors:  P Bareille; M MacSwiney; A Albanese; C De Vile; R Stanhope
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

4.  Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system.

Authors:  R Stanhope; A Albanese; L Moyle; G Hamill
Journal:  Arch Dis Child       Date:  1992-08       Impact factor: 3.791

5.  Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use.

Authors:  Anita Hokken-Koelega; Alexandra Keller; Viatcheslav Rakov; Stefan Kipper; Jovanna Dahlgren
Journal:  ISRN Endocrinol       Date:  2011-09-20

6.  Understanding and meeting the needs of those using growth hormone injection devices.

Authors:  Hervé Dumas; Paris Panayiotopoulos; Dorothy Parker; Vincent Pongpairochana
Journal:  BMC Endocr Disord       Date:  2006-10-11       Impact factor: 2.763

7.  Patients' Perception of the Use of the EasyPod™ Growth Hormone Injector Device and Impact on Injection Adherence: A Multi-Center Regional Study.

Authors:  Asma Deeb; Saif Al Yaarubi; Bassam Bin Abbas; Jamal Al Jubeh; Deepti Chaturvedi; Noura Al Hassani; Angham Mutair; Neamat Al Masri; Yazan Al Sanad; Azza Al Shidhani; Noha Samir Mahmoud; Abdullah Alherbish; Martin O Savage
Journal:  Front Pediatr       Date:  2022-02-28       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.